Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Jan;169(1):71-9.
doi: 10.1176/appi.ajp.2011.11030347. Epub 2011 Oct 31.

Risk of mortality among individual antipsychotics in patients with dementia

Helen C Kales  1 , Hyungjin Myra Kim, Kara Zivin, Marcia Valenstein, Lisa S Seyfried, Claire Chiang, Francesca Cunningham, Lon S Schneider, Frederic C Blow
Affiliations

Risk of mortality among individual antipsychotics in patients with dementia

Helen C Kales et al. Am J Psychiatry. 2012 Jan.

Abstract

Objective: The use of antipsychotics to treat the behavioral symptoms of dementia is associated with greater mortality. The authors examined the mortality risk of individual agents to augment the limited information on individual antipsychotic risk.

Method: The authors conducted a retrospective cohort study using national data from the U.S. Department of Veterans Affairs (fiscal years 1999-2008) for dementia patients age 65 and older who began outpatient treatment with an antipsychotic (risperidone, olanzapine, quetiapine, or haloperidol) or valproic acid and its derivatives (as a nonantipsychotic comparison). The total sample included 33,604 patients, and individual drug groups were compared for 180-day mortality rates. The authors analyzed the data using multivariate models and propensity adjustments.

Results: In covariate-adjusted intent-to-treat analyses, haloperidol was associated with the highest mortality rates (relative risk=1.54, 95% confidence interval [CI]=1.38-1.73) followed by risperidone (reference), olanzapine (relative risk=0.99, 95% CI=0.89-1.10), valproic acid and its derivatives (relative risk=0.91, 95% CI=0.78-1.06), and quetiapine (relative risk=0.73, 95% CI=0.67-0.80). Propensity-stratified and propensity-weighted models as well as analyses controlling for site of care and medication dosage revealed similar patterns. The mortality risk with haloperidol was highest in the first 30 days but decreased significantly and sharply thereafter. Among the other agents, mortality risk differences were most significant in the first 120 days and declined in the subsequent 60 days during follow-up.

Conclusions: There may be differences in mortality risks among individual antipsychotic agents used for treating patients with dementia. The use of valproic acid and its derivatives as alternative agents to address the neuropsychiatric symptoms of dementia may carry associated risks as well.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Covariate Adjusted Survival Function by Days of Exposure
See this image and copyright information in PMC

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Saha S, Robinson S, Bainco T, Schechtel M, Hickam D. In A Summary for Clinicians and Policy Makers. Agency for Healthcare Research and Quality; 2007. Off-Label Use of Atypical Antipsychotic Drugs; pp. 1–4. - PubMed
    1. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA. 2005;294(15):1934–1943. - PubMed
    1. Kales HC, Valenstein M, Kim HM, McCarthy JF, Ganoczy D, Cunningham F, Blow FC. Mortality risk in patients with dementia treated with antipsychotics versus other psychiatric medications. The American journal of psychiatry. 2007;164(10):1568–1576. quiz 1623. - PubMed
    1. Gill SS, Bronskill SE, Normand SL, Anderson GM, Sykora K, Lam K, Bell CM, Lee PE, Fischer HD, Herrmann N, et al. Antipsychotic drug use and mortality in older adults with dementia. Ann Intern Med. 2007;146(11):775–786. - PubMed
    1. Ballard C, Hanney M, Theodoulou M, Douglas S, McShane R, Kossakowski K, Gill R, Juszczak E, Yu L-M, Jacoby R. The dementia antipsychotic withdrawal trial (DART-AD): long-term follow- up of a randomised placebo-controlled trial. Lancet neurology. 2009;8(2):151–157. - PubMed

Publication types

MeSH terms